New Orleans – 5pm on Sunday at the annual meeting of the American Society of Hematology (ASH) saw the start of the oral sessions, where the latest research and clinical trial data is presented.
I attended the novel agents in lymphoma session, and this post offers some top-line “notes from the road” on the following presentations:
Abstract 85: Idelalisib Ph2 data in patients with double (Rituximab and Alkylating Agent) refractory indolent Non-Hodgkin Lymphoma (iNHL).
Abstract 86: SAR245409 Monotherapy in relapsed/refractory Follicular Lymphoma from phase 2 ARD12130 study.
Abstract 87: Phase 2 study of BAY 80-6946 (copanlisib) in relapsed/refactory, indolent or aggressive lymphomas.
To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below…
Originally, I was thinking of doing an in-depth review of lymphomas i.e. non-Hodgkin’s lymphoma (NHL), which involve 85% of lymphomas and Hodgkin’s lymphoma (HL), which take up the remaining 15%. This topic, however, has been largely done to death already.
There are are some very useful sources of carefully curated content that I enjoy following every year and in this post I’m going to direct you to some of those and highlight where I think the critical topics are in lymphomas.
Companies mentioned: Roche, GSK, AbbVie, Pharmacyclics, Gilead, Infinity, Seattle Genetics
Drugs mentioned: Rituxan, Arzerra, Gazyva, ABT-199, ibrutinib, idelalisib, IPI-145, Adcetris
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.